In one paragraphArticle in Oncogene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
25 authors.
Gianluca CivenniInstitute of Oncology Research (IOR), Università della Svizzera italiana (USI), Bellinzona, Switzerland.ORCID 0000-0003-1921-161X Giada SandriniInstitute of Oncology Research (IOR), Università della Svizzera italiana (USI), Bellinzona, Switzerland.ORCID 0000-0002-7294-3863 Jessica MerullaInstitute of Oncology Research (IOR), Università della Svizzera italiana (USI), Bellinzona, Switzerland.
Carola MusumeciInstitute of Oncology Research (IOR), Università della Svizzera italiana (USI), Bellinzona, Switzerland.ORCID 0009-0002-7611-0743 Elisa FedericiInstitute of Oncology Research (IOR), Università della Svizzera italiana (USI), Bellinzona, Switzerland.ORCID 0009-0005-8531-1864 Aleksandra KokanovicInstitute of Oncology Research (IOR), Università della Svizzera italiana (USI), Bellinzona, Switzerland.
Simone MosoleInstitute of Oncology Research (IOR), Università della Svizzera italiana (USI), Bellinzona, Switzerland.ORCID 0009-0008-4400-3488 Dheeraj ShindeInstitute of Oncology Research (IOR), Università della Svizzera italiana (USI), Bellinzona, Switzerland.ORCID 0000-0002-5113-3167 Elisa SorrentiInstitute of Oncology Research (IOR), Università della Svizzera italiana (USI), Bellinzona, Switzerland.ORCID 0000-0002-3905-647X Alyssa J J PaganoniInstitute of Oncology Research (IOR), Università della Svizzera italiana (USI), Bellinzona, Switzerland.ORCID 0000-0001-9393-9356 Martina MarchettiInstitute of Oncology Research (IOR), Università della Svizzera italiana (USI), Bellinzona, Switzerland.
Riccardo ValzelliInstitute of Oncology Research (IOR), Università della Svizzera italiana (USI), Bellinzona, Switzerland.ORCID 0009-0007-2037-2513 Domenico AlbinoInstitute of Oncology Research (IOR), Università della Svizzera italiana (USI), Bellinzona, Switzerland.ORCID 0000-0001-6249-4163 Matteo PecoraroInstitute for Research in Biomedicine (IRB), Università della Svizzera italiana (USI), Bellinzona, Switzerland.ORCID 0009-0002-8105-9671 Andrea RinaldiInstitute of Oncology Research (IOR), Università della Svizzera italiana (USI), Bellinzona, Switzerland.ORCID 0000-0003-3234-0563 Marco BolisInstitute of Oncology Research (IOR), Università della Svizzera italiana (USI), Bellinzona, Switzerland.ORCID 0000-0003-4377-5079 Roger GeigerInstitute of Oncology Research (IOR), Università della Svizzera italiana (USI), Bellinzona, Switzerland.ORCID 0000-0002-8016-1669 Tobias WingeInstitut für Pharmazeutische und Medizinische Chemie, Westfälische Wilhelms-Universität Münster, Münster, Germany.
Catharina HoltschulteInstitut für Pharmazeutische und Medizinische Chemie, Westfälische Wilhelms-Universität Münster, Münster, Germany.
Erik LauriniMolecular Biology and Nanotechnology Laboratory (MolBNL@UniTS), DEA, University of Trieste, Trieste, Italy.
Sabrina PriclMolecular Biology and Nanotechnology Laboratory (MolBNL@UniTS), DEA, University of Trieste, Trieste, Italy.ORCID 0000-0001-8380-4474 Giuseppina M CarboneInstitute of Oncology Research (IOR), Università della Svizzera italiana (USI), Bellinzona, Switzerland.ORCID 0000-0003-4652-585X Bernhard WünschInstitut für Pharmazeutische und Medizinische Chemie, Westfälische Wilhelms-Universität Münster, Münster, Germany.ORCID 0000-0002-9030-8417 Carlo V CatapanoInstitute of Oncology Research (IOR), Università della Svizzera italiana (USI), Bellinzona, Switzerland. carlo.catapano@ior.usi.ch.ORCID 0000-0002-7079-557X Funding
Krebsliga Schweiz (Ligue Suisse Contre le Cancer) KLS-4569-08-2018Krebsliga Schweiz (Ligue Suisse Contre le Cancer) KLS-4899-08-2019Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) SNSF-310030_189081Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) SNSF-310030L_170182Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) SNSF-IZLSZ3_170898
6 · The paper itselfAbstract
Cancer stem cells (CSCs) are pervasively present in human cancers and have a fundamental role in treatment failure and disease recurrence. Identifying critical elements that sustain the CSC phenotype may lead to novel strategies for cancer treatment. Here, we provide evidence of an essential link between the σ
Indexed as
Neoplastic Stem CellsProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantReceptors, sigmaAnimalsbeta CateninCell Line, TumorGene Expression Regulation, NeoplasticHumansMaleMiceMitochondriaSigma-1 ReceptorSignal Transductionbeta CateninReceptors, sigmaSigma-1 Receptor
Identifiers
PMID40897798
PMCPMC12518131
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390